{"filing":{"accession_number":"0001104659-26-079360","cik":"0001875558","ticker":"NVCT","company_name":"Nuvectis Pharma, Inc.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"tm2619346d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926079360/tm2619346d1_8k.htm"},"events":[{"id":15000,"run_id":13381,"accession_number":"0001104659-26-079360","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Nuvectis entered into an underwriting agreement on June 29, 2026 to conduct a registered public offering of 5,000,000 shares of common stock at $20.00 per share, generating $100 million in gross proceeds (or $115 million if underwriters exercise their 30-day option for 750,000 additional shares), resulting in net proceeds of approximately $93–107 million after underwriting fees.","company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12595,"accession_number":"0001104659-26-079360","item_number":"1.01","item_title":"Entry","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Nuvectis entered into an underwriting agreement on June 29, 2026 to sell 5,000,000 shares of common stock at $20.00 per share in a firm commitment public offering, with expected gross proceeds of $100 million (or $115 million if the underwriters exercise their 30-day option for 750,000 additional shares). This is a registered public offering of equity securities that will dilute existing shareholders. The Item 1.01 disclosure of the underwriting agreement, combined with the substantial capital raise (~$93–107 million net), makes this a material dilutive issuance typical of equity financing by a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:17:48.663740+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12596,"accession_number":"0001104659-26-079360","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Nuvectis announced a registered public offering of 5,000,000 shares of common stock at $20.00 per share, generating $100 million in gross proceeds, with an additional 30-day option for underwriters to purchase 750,000 shares. This is a material registered equity issuance that dilutes existing shareholders and is disclosed under Item 8.01 via press releases filed as Exhibits 99.1 and 99.2.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:17:48.663740+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12595,"accession_number":"0001104659-26-079360","item_number":"1.01","item_title":"Entry","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Nuvectis entered into an underwriting agreement on June 29, 2026 to sell 5,000,000 shares of common stock at $20.00 per share in a firm commitment public offering, with expected gross proceeds of $100 million (or $115 million if the underwriters exercise their 30-day option for 750,000 additional shares). This is a registered public offering of equity securities that will dilute existing shareholders. The Item 1.01 disclosure of the underwriting agreement, combined with the substantial capital raise (~$93–107 million net), makes this a material dilutive issuance typical of equity financing by a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:17:48.663740+00:00","company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","filing_date":"2026-06-30"},{"id":12596,"accession_number":"0001104659-26-079360","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Nuvectis announced a registered public offering of 5,000,000 shares of common stock at $20.00 per share, generating $100 million in gross proceeds, with an additional 30-day option for underwriters to purchase 750,000 shares. This is a material registered equity issuance that dilutes existing shareholders and is disclosed under Item 8.01 via press releases filed as Exhibits 99.1 and 99.2.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:17:48.663740+00:00","company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","filing_date":"2026-06-30"}]}